NASDAQ$JYNT
The Joint Corp · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
The Joint Corp. Q2 2024 financial results were reported, with revenue growing 3%, system-wide sales increasing 8%, and system-wide comp sales up 2% compared to Q2 2023.
The Joint Corp. reported a 3% increase in revenue to $30.3 million for Q2 2024. System-wide sales increased by 8% to $129.6 million, and system-wide comp sales grew by 2%. The company reported a net loss of $3.6 million, including $1.5 million in litigation expense and $1.4 million in loss on disposition or impairment. Adjusted EBITDA was $2.1 million.
- Revenue grew 3% to $30.3 million compared to Q2 2023.
- System-wide sales increased 8% to $129.6 million.
- System-wide comp sales increased 2%.
- The total clinic count reached 960 at June 30, 2024.
Headline financials
Revenue & EPS history
The Joint · Revenue · Quarterly
$30.3M
Forward guidance
The company reiterated all elements of its guidance.
Tailwinds
- System-wide sales are expected to be between $530 and $545 million, compared to $488.0 million in 2023.
- System-wide comp sales for all clinics open 13 months or more are expected to be in the mid-single digits in 2024.
- New franchised clinic openings, excluding the impact of refranchised clinics, are expected to be between 60 and 75, compared to 104 in 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
+1.5%
Avg return
Earnings day
+3.3%
Avg return
5 days after
+3.8%
Avg return
30 days after
53%
25 / 47 earnings
Positive
+26.0%
Q1 2024
Best reaction
-42.3%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.5% | -2.2% | -6.0% | |
| Q4 2025 | +2.0% | +1.9% | +6.3% | |
| Q3 2025 | -3.9% | +4.6% | +6.1% | |
| Q1 2025 | -5.0% | -5.2% | +14.1% | |
| Q4 2024 | +4.6% | +17.9% | -1.3% | |
| Q3 2024 | -2.8% | -1.7% | -3.1% | |
| Q2 2024 | -5.1% | -3.6% | -8.7% | |
| Q1 2024 | +26.0% | +26.1% | +17.4% | |
| Q4 2023 | +25.7% | +29.8% | +34.8% | |
| Q3 2023 | +1.3% | +4.6% | +15.1% | |
| Q2 2023 | +1.8% | -0.2% | -14.6% | |
| Q1 2023 | -3.1% | -2.2% | -11.2% | |
| Q4 2022 | +2.3% | +1.4% | -1.2% | |
| Q3 2022 | -4.6% | -3.3% | +1.6% | |
| Q2 2022 | +15.2% | +7.8% | -9.6% | |
| Q1 2022 | -42.3% | -43.6% | -46.2% | |
| Q4 2021 | -9.9% | -20.8% | -24.7% | |
| Q3 2021 | +5.8% | +8.6% | -21.8% | |
| Q2 2021 | +18.9% | +17.8% | +22.0% | |
| Q1 2021 | -4.5% | -6.8% | +28.2% | |
| Q4 2020 | -10.0% | -14.9% | -7.0% | |
| Q3 2020 | +7.1% | +28.5% | +35.2% | |
| Q2 2020 | +13.5% | +15.1% | +23.7% | |
| Q1 2020 | +9.9% | +8.8% | +35.6% | |
| Q4 2019 | -3.0% | -10.8% | -42.2% | |
| Q3 2019 | -3.6% | -10.3% | -13.1% | |
| Q2 2019 | -0.1% | +0.0% | -6.2% | |
| Q1 2019 | +8.7% | +4.4% | -7.2% | |
| Q4 2018 | +12.6% | +21.5% | +42.4% | |
| Q3 2018 | +3.8% | +5.5% | +0.5% | |
| Q2 2018 | +8.5% | +3.9% | +2.8% | |
| Q1 2018 | -3.0% | +1.8% | +1.9% | |
| Q4 2017 | +8.2% | +23.7% | +35.9% | |
| Q3 2017 | +16.2% | +23.0% | +8.6% | |
| Q2 2017 | +3.6% | +2.7% | +34.5% | |
| Q1 2017 | +7.3% | +2.6% | -1.3% | |
| Q4 2016 | -15.3% | -11.4% | -15.8% | |
| Q3 2016 | +3.7% | +6.1% | -6.5% | |
| Q2 2016 | -0.5% | -0.9% | +28.9% | |
| Q1 2016 | -0.0% | — | — | |
| Q4 2015 | -21.5% | — | — | |
| Q3 2015 | -6.1% | — | — | |
| Q2 2015 | +1.3% | — | — | |
| Q1 2015 | +6.2% | — | — | |
| Q4 2014 | +4.0% | — | — | |
| Q3 2014 | -1.6% | — | — | |
| Q3 2013 | -1.6% | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro